HB 7245 – Rhode IslandStatus: Inactive / Dead
Year Introduced: 2022
Allows drug cost transparency by requiring reports be submitted by drug manufacturers, pharmacy benefit managers and health benefit plan insurers for analysis to the director of the department of business regulation regarding prescription drugs.
Return to Database Search
© 2018- The SLIHCQ Database. Initial funding for this project was provided by the Robert Wood Johnson Foundation. The views expressed here do not necessarily reflect the views of the Foundation.
No items found